Get answers to questions you may have about the application process or how to request medicine
Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying uninsured patients access Amgen medicines at no cost.
Amgen Safety Net Foundation supports financially needy uninsured patients and certain underinsured patients who do not have insurance coverage for their Amgen medication. Qualifying uninsured patients must not be eligible for Medicaid, Medicare, or any other financial support options.
Amgen Safety Net Foundation income requirements are based on a percentage of the Federal Poverty Level, adjusted for household size.
Eligible patients are enrolled for a period up to 12 months. To re-enroll in Amgen Safety Net Foundation, patients must submit a new application.
To re-enroll in the Amgen Safety Net Foundation, patients must submit a new application.
Yes, if you meet the eligibility requirements, you may qualify for Amgen Safety Net Foundation support and receive certain Amgen medications at no cost.
Maybe. Amgen Safety Net Foundation supports underinsured patients who have limited coverage for Amgen medications in certain situations.
Yes. Patients who appear eligible for Medicaid are not eligible for Amgen Safety Net Foundation. If you have been denied Medicaid within the last 90 days please include a copy of the denial letter received from the Medicaid office with the application submission.
Amgen Safety Net Foundation will provide assistance for any medically appropriate use of Amgen products as determined by the patient's physician.
The prescription model applies to products that require a product prescription and delivery of medication in advance of administration. Under this model, the patient submits a patient application and the provider completes a product prescription form, or submits an original script to the Foundation for the applicable Amgen product. Foundation products included in the prescription model are Aimovig™ (erenumab-aooe), Corlanor® (ivabradine), Enbrel® (etanercept), Prolia® (denosumab) injection for bone health, Repatha® (evolocumab) and Sensipar® (cinacalcet) Tablets. Amgen Safety Net Foundation ships prescription products directly to the patient except Prolia®, which is shipped directly to the provider.
Amgen Safety Net Foundation offers replacement product for physician-administered medications. Under this model, providers administer Amgen product from their existing commercial stock to qualifying Foundation patients and then order replacement for this product from the Foundation. These products must be administered in an outpatient setting to be eligible for replacement. Foundation products included in the replacement model are Aranesp® (darbepoetin alfa), AVSOLA™ (infliximab-axxq), EPOGEN® (Epoetin alfa) for dialysis only, EVENITY™ (romosozumab-aqqg), KANJINTI™ (trastuzumab-anns), Kyprolis® (carfilzomib), MVASI™ (bevacizumab-awwb), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim), Nplate® (romiplostim), Parsabiv™ (etelcalcetide), Prolia® (denosumab) injection, Vectibix® (panitumumab) injection, and XGEVA® (denosumab).
After product has been administered to the patient, providers can request replacement by completing the Product Replacement Request Form. Providers can submit multiple product replacement requests for multiple patients and products on one form as long as the facility customer number and shipping address are the same.
Yes, the replacement model allows for a six-month retroactive policy for replacement products. Once a patient becomes enrolled, replacement product may be requested for dates of administration up to six months prior to the patient's enrollment start date. On Demand and Prescription model requests for administration in the past will not be processed. On Demand and Prescription model products are delivered in advance of administration and are not eligible for replacement after they have been administered.
Amgen Safety Net Foundation offers shipment in advance of administration for certain physician administered medications. Under this model, providers complete an On Demand Product Request Form after the patient has been enrolled to the Foundation. Foundation products included in the On Demand model are Blincyto® (blinatumomab) for injection and IMLYGIC® (talimogene laherparepvec). Amgen Safety Net Foundation ships On Demand products directly to the provider in advance of administration.
All foundation products except Epogen® (epoetin alfa) for dialysis-use only can be shipped in exact quantities under the combined pharmacy/wholesaler model if the physician signature is provided on the product replacement order form. For Epogen® for dialysis-use only, multidose product is not shipped through the break pack model; 200,000 units must be accumulated in order to ship a full pack.
For Aimovig support, call us at 1-800-932-3060 Monday through Friday from 8am to 8pm Eastern Time. You can fax us at 1-833-959-1409 or mail documents to PO Box 19148, Lenexa, KS 66285.
For support of all other Amgen medicines call us at (888) 762-6436 Monday through Friday from 8am to 8pm Eastern Time. You can fax us at 1-866-549-7239 or mail documents to P.O. Box 18769, Louisville, KY 40261.
Amgen Safety Net Foundation does not charge patients a fee for its assistance. Amgen Safety Net Foundation is not affiliated with third parties who charge a fee for assistance with enrollment or medication refills. If you are being charged a monthly fee for support from the Amgen Safety Net Foundation, the organization billing you is not the Amgen Safety Net Foundation and you are being charged for support that the Amgen Safety Net Foundation can provide to you directly at no cost.